Lack of association between the CXCL12 rs501120 polymorphism and cardiovascular disease in Spanish patients with rheumatoid arthritis

López‐Mejías, Raquel; García-Bermúdez, Mercedes; González‐Juanatey, Carlos; Castañeda, Santos; Miranda‐Filloy, José A.; Gómez-Vaquero, Carmen; Fernández‐Gutiérrez, Benjamín; Balsa, Alejandro; Pascual‐Salcedo, Dora; Blanco, Ricardo; González‐Álvaro, Isidoro; Llorca, Javier; Martı́n, Javier

doi:10.1016/j.humimm.2012.02.012

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, our findings are in contrast with a previous, similarly powered, Spanish study that reported a lack of association between the proxy for rs1746048 (ie, rs501120) and CVD outcome 8. This demonstrates variability of association between different genetic populations, and future replication studies in populations of similar genetic background are, therefore, required, as well as studies to determine the causal effect at the CXCL12 locus, and to assess the correlation between plasma CXCL12 levels and CVD outcome in RA.…”

contrasting

confidence: 99%

“…Several studies have highlighted an important role for CXCL12 in RA by demonstrating increased levels of CXCL12 in synovial fluid, as well as upregulation of CXCL12 mRNA in synovial fibroblasts, which may contribute to sustained inflammation 7. However, a large study of Spanish patients with established RA did not detect an association with CVD outcome and a variant at the CXCL12 locus (rs501120),8 which is in complete linkage disequilibrium with rs1746048 (r 2 =1.0) 6…”

mentioning

confidence: 99%

See 1 more Smart Citation

Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register: Table 1

et al. 2015

View full text Add to dashboard Cite

contrasting

confidence: 99%

mentioning

confidence: 99%

Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register: Table 1

et al. 2015

View full text Add to dashboard Cite

“…However, we did not observe any significant association with clinical or subclinical CV disease [36]. …”

Section: Cytokine and Chemokine Genesmentioning

confidence: 98%

Genetic Markers of Cardiovascular Disease in Rheumatoid Arthritis

Rodríguez‐Rodríguez

López‐Mejías

García-Bermúdez

et al. 2012

Mediators of Inflammation

Self Cite

View full text Add to dashboard Cite

Cardiovascular (CV) disease is the most common cause of premature mortality in patients with rheumatoid arthritis (RA). It is the result of an accelerated atherosclerotic process. Both RA and atherosclerosis are complex polygenic diseases. Besides traditional CV risk factors and chronic inflammation, a number of studies have confirmed the role of genetic factors in the development of the atherogenesis observed in RA. In this regard, besides a strong association between the HLA-DRB1∗04 shared epitope alleles and both endothelial dysfunction, an early step in the atherosclerotic process, and clinically evident CV disease, other polymorphisms belonging to genes implicated in inflammatory and metabolic pathways, located inside and outside the HLA region, such as the 308 variant (G > A, rs1800629) of the TNFA locus, the rs1801131 polymorphism (A > C; position + 1298) of the MTHFR locus, or a deletion of 32 base pairs on the CCR5 gene, seem to be associated with the risk of CV disease in patients with RA. Despite considerable effort to decipher the genetic basis of CV disease in RA, further studies are required to better establish the genetic influence in the increased risk of CV events observed in patients with RA.

show abstract

Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers

López‐Mejías

Castañeda

González‐Juanatey

et al. 2016

Autoimmunity Reviews

111

View full text Add to dashboard Cite

Cardiovascular disease (CV) is the most common cause of premature mortality in patients with rheumatoid arthritis (RA). This is the result of an accelerated atherosclerotic process. Adequate CV risk stratification has special relevance in RA to identify patients at risk of CV disease. However, current CV risk screening and management strategies underestimate the actual CV risk in RA. Consequently, the search for additional tools that may help to identify those patients at high CV risk has become a key objective in the last years. In this regard, non-invasive surrogates, such as carotid ultrasonography, have been found to be excellent predictors of future CV events. In addition, several studies have revealed the relevance of a genetic component in the development of CV disease in RA patients. Besides an association with HLA-DRB1* shared epitope alleles other gene polymorphisms located inside and outside the HLA seem to influence the risk of cardiovascular disease in RA. Moreover, serum levels of some metabolic syndrome-related biomarkers, adipokines such as adiponectin and biomarkers of endothelial cell activation and inflammation such as Osteoprotegerin and Asymmetric dimethylarginine have recently been found useful for the prediction of CV disease in these patients. An update of the current knowledge on these potential markers, especially focused on new genetic and serological biomarkers is shown in this review.

show abstract

Lack of association between the CXCL12 rs501120 polymorphism and cardiovascular disease in Spanish patients with rheumatoid arthritis

Cited by 4 publications

References 19 publications

Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register: Table 1

Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register: Table 1

Genetic Markers of Cardiovascular Disease in Rheumatoid Arthritis

Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers

Contact Info

Product

Resources

About